Improved pharmaceutical lubricants comprising finely divided magnesium or calcium stearate coated with a surfactant are disclosed. The improved lubricants greatly enhance disintegration and dissolution time of tablets and capsules prepared therefrom without loss in essential pharmaceutical lubricant properties.
This invention relates to urea-free high solids content aqueous calcium stearate dispersions useful as lubricating agents in paper and paperboard coating compositions.
In a process for the manufacture of a moulded product by compression of a powder or granules in a die, a powdered die lubricant is used, lubricant particles are electrically charged and the charged particles are fed to the die in advance of the moulding powder. An apparatus for carrying out the process is also provided, the apparatus including a first feed for feeding a powdered lubricant to the die, a second feed for feeding moulded powder to the die after the powdered lubricant, and means for maintaining the electrical potential of the die at a predetermined value different from that of the powdered lubricant.
An apparatus for carrying out a process for the manufacture of a moulded product by compression of a powder or granules in a die, wherein a powdered die lubricant is used, lubricant particles are electrically charged and the charged particles are fed to the die in advance of the moulding powder is provided. The apparatus includes a first feed for feeding a powdered lubricant to the die, a second feed for feeding powder to the die after the powdered lubricant, and means for maintaining the electrical potential of the die at a predetermined value different from that of the powdered lubricant.
A novel method of delivering drugs and diagnostics across the blood-brain barrier or blood-nerve barrier is disclosed. Drugs or diagnostic agents are incorporated into nanoparticles which have been fabricated in conventional ways. These nanoparticles are then coated with additional surfactant and given to the body of animals or humans. This allows drugs or diagnostic agents to cross the blood-brain barrier (bbb) to achieve one or more of the following benefits: (1) reducing the dose of a therapeutic drug or diagnostic agent which, when given peripherally, maintains the biological or diagnostic potency in the nervous system, (2) allowing drugs that normally do not cross the bbb to penetrate into the nervous system, and (3) reducing the peripheral side effects by increasing the relative amount of the drug reaching the brain.
